Human ACE-2 PE-conjugated Antibody Summary
Gln18-Ser740
Accession # Q9BYF1
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of ACE-2 in Human PBMC by Flow Cytometry. Human PBMC were stained with (A) Rat Anti-Human ACE-2 PE-conjugated Monoclonal Antibody (Catalog # FAB9334P) or (B) Rat IgG2b Isotype Control Antibody (IC013P) and Mouse anti-Human CD14 APC-conjugated Monoclonal Antibody (FAB3832A). Staining was performed using our Staining Membrane-associated Proteins protocol.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: ACE-2
Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE (1, 2). ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues (1, 3). ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo (4-6), functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters (1, 2). Through thesFAB9334Pe functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury (4, 7), heart disease (8), liver and lung fibrosis (9), inflammatory lung disease (10), and cardiopulmonary disease (11). Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail (12). The N-terminal peptidase region is required for binding to SARS-CoV and SARSCoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters (2). The peptidase domain contains a long deep cleft that undergoes a large hinge-bending movement at substrate and inhibitor binding (12). Classical ACE inhibitors such as captopril and lisinopril do not inhibit ACE-2 activity and inhibitors of ACE-2 do not inhibit ACE activity (13).
- Kuba, K. et al. (2010) Pharmacol. Ther. 128:119.
- Yan, et al. (2020) Science 367:1444.
- Tipnis, S.R. et al. (2000) J. Biol. Chem. 275:33238.
- Kuba, K. et al. (2005) Nature Med. 11:875.
- Hoffman, M. et al. (2020) Cell. 181:1.
- Wrapp, et al. (2020) Science 367:1260.
- Imai, Y. et al. (2005) Nature 436:112.
- Huang, L. et al. (2003) J. Biol. Chem. 278:15532.
- Schrom, E. et al. (2017) Mol. Therapy Nuc. Acid 7:350.
- Jia, H. et al. (2016) Shock. 46:239.
- Cole-Jeffrey, C.T. et al. (2015) J. Cadiovasc. Pharmacol. 66:540.
- Towler, P. et al. (2004) J. Biol. Chem. 279:17996.
- Crackower, M.A. et al. (2002) Nature 417:822.
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human ACE-2 PE-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human ACE-2 PE-conjugated Antibody and earn rewards!
Have you used Human ACE-2 PE-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
